Common use of Information and Reporting Clause in Contracts

Information and Reporting. Soligenix will keep Intrexon informed about Soligenix’s efforts to develop and Commercialize Soligenix Products, including reasonable and accurate summaries of Soligenix’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated), including regulatory plans, marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Soligenix Products, including initiation or completion of a Regulatory Trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse safety events, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.7 above, Soligenix shall also provide to Intrexon copies of all final Regulatory Trial protocols and reports, and regulatory correspondence and filings generated by Soligenix as soon as practical after they become available. Intrexon will keep Soligenix informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Soligenix and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Soligenix Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix Synthetic will keep Intrexon informed about SoligenixSynthetic’s efforts to develop and Commercialize Soligenix commercialize Synthetic Products, including reasonable and accurate summaries of SoligenixSynthetic’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Soligenix Synthetic Products, including initiation or completion of a Regulatory Trialclinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse clinical safety eventsevent, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.7 3.8 above, Soligenix Synthetic shall also provide to Intrexon copies of all final Regulatory Trial preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Soligenix Synthetic as soon as practical after they become available. Intrexon will keep Soligenix informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. as practical after they become available. Intrexon will keep Synthetic informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Synthetic Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Anti-Infectives Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Soligenix Synthetic and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Soligenix Synthetic Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix Oragenics will keep Intrexon EGI informed about Soligenix’s Oragenics’ efforts to develop and Commercialize Soligenix commercialize Oragenics Products, including reasonable and accurate summaries of Soligenix’s Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Soligenix Oragenics Products, including initiation or completion of a Regulatory Trialclinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse clinical safety eventsevent, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.7 3.8 above, Soligenix Oragenics shall also provide to Intrexon EGI copies of all final Regulatory Trial preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Soligenix Oragenics as soon as practical after they become available. Intrexon EGI will keep Soligenix Oragenics informed about IntrexonEGI’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Oragenics Products (and Intrexon EGI Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Lantibiotics Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. EGI Channel Technology and Intrexon EGI Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Soligenix Oragenics and Intrexon EGI will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Soligenix Oragenics Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix Fibrocell will keep Intrexon informed about SoligenixFibrocell’s efforts to develop and Commercialize Soligenix Collaboration Products, including reasonable and accurate summaries of SoligenixFibrocell’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated), including preclinical, clinical and regulatory plans, marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Soligenix Collaboration Products, including initiation or completion of a Regulatory Trialclinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse clinical safety eventsevent, receipt of Regulatory Approvalregulatory approval, or commercial launch, and manufacturing and pricing information. As set forth in Section 3.7 3.8 above, Soligenix Fibrocell shall also provide to Intrexon copies of all final Regulatory Trial preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Soligenix Fibrocell as soon as practical after they become available. Intrexon will keep Soligenix Fibrocell informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Collaboration Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord accordance with Section 4.2 above, such disclosures by Soligenix Fibrocell and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Soligenix Collaboration Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix BioLife will keep Intrexon informed about SoligenixBioLife’s efforts to develop and Commercialize Soligenix and, upon successful execution by BioLife of its option under Section 5.1, commercialize BioLife Products, including reasonable and accurate summaries of Soligenix’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated), including regulatory plans, marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Soligenix Products, including initiation or completion of a Regulatory Trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse safety events, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.7 above, Soligenix shall also provide to Intrexon copies of all final Regulatory Trial protocols and reports, and regulatory correspondence and filings generated by Soligenix as soon as practical after they become available. Intrexon will keep Soligenix informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. BioLife’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or commercialization of the BioLife Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical safety event, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.8 above, BioLife shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by BioLife as soon as practical after they become available. Intrexon will keep BioLife informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for BioLife Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the SMA Therapeutics Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Soligenix BioLife and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Soligenix BioLife Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix Synthetic will keep Intrexon informed about SoligenixSynthetic’s efforts to develop and Commercialize Soligenix Collaboration Products, including reasonable and accurate summaries of SoligenixSynthetic’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated)) for Collaboration Products, including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Soligenix Collaboration Products, including initiation or completion of a Regulatory Trialclinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse clinical safety eventsevent, receipt of Regulatory Approvalregulatory approval, or commercial launch. As set forth in Section 3.7 3.8 above, Soligenix Synthetic shall also provide to Intrexon copies of all final Regulatory Trial preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Soligenix Synthetic as soon as practical after they become available. Intrexon will keep Soligenix Synthetic informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Collaboration Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein, such disclosures by Synthetic and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Collaboration Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Soligenix and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Soligenix Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix Oragenics will keep Intrexon informed about Soligenix’s Oragenics’ efforts to develop and Commercialize Soligenix commercialize Oragenics Products, including reasonable and accurate summaries of Soligenix’s Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Soligenix Oragenics Products, including initiation or completion of a Regulatory Trialclinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse clinical safety eventsevent, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.7 3.8 above, Soligenix Oragenics shall also provide to Intrexon copies of all final Regulatory Trial preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Soligenix Oragenics as soon as practical after they become available. Intrexon will keep Soligenix Oragenics informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Lantibiotics Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Soligenix Oragenics and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Soligenix Oragenics Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Soligenix Synthetic will keep Intrexon informed about SoligenixSynthetic’s efforts to develop and Commercialize Soligenix commercialize Synthetic Products, including reasonable and accurate summaries of SoligenixSynthetic’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Soligenix Synthetic Products, including initiation or completion of a Regulatory Trialclinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse clinical safety eventsevent, receipt of Regulatory Approval, or commercial launch. As set forth in Section 3.7 3.8 above, Soligenix Synthetic shall also provide to Intrexon copies of all final Regulatory Trial preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Soligenix Synthetic as soon as practical after they become available. Intrexon will keep Soligenix Synthetic informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Synthetic Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Anti-Infectives Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Soligenix Synthetic and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Soligenix Synthetic Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.